Volume 4, Issue 3, September 2020, Page: 127-130
Advances in the Value of Cardiac Troponin and ST Segment Depression in Predicting Coronary Artery Disease in Patients with Paroxysmal Supraventricular Tachycardia
Pan Yun, Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, China
Chen Dongdong, Department of Cardiology, The First Affiliated Hospital of Jinan University, Guangzhou, China
Received: Aug. 2, 2020;       Accepted: Aug. 11, 2020;       Published: Aug. 13, 2020
DOI: 10.11648/j.ccr.20200403.18      View  118      Downloads  49
Abstract
Paroxysmal supraventricular tachycardia (PSVT) is similar to coronary artery disease (CAD) in that it is often accompanied by chest pain, ST segment depression or elevated cardiac troponin in the electrocardiogram (ECG). Studies have shown that only 20%-40% of these patients are diagnosed with CAD by coronary angiography and even lower in foreign countries. Therefore, a noninvasive and simple method is urgently needed in practice to determine the high-risk population of PSVT patients with CAD, so as to avoid excessive examination and waste of medical resources. Cardiac troponin and ECG are favored in clinic because of their simple, economical and non-invasive detection methods. By analyzing the mechanism, it is concluded that elevated troponin and ST segment depression are of low predictive value for CAD diagnosis in PSVT patients, and it is necessary to further evaluate the risk factors for cardiovascular disease in these patients to determine whether coronary angiography is required. However, it is worth noting that ST segment depression in PSVT patients may be associated with coronary microcirculation lesions. Future research should also start from the pathogenesis, symptoms and characteristics of coronary microcirculation lesions to find more similarities and differences with PSVT combined with ST segment depression. This paper may contribute to a better understanding of troponin elevation and ST segment depression in PSVT patients.
Keywords
Paroxysmal Supraventricular Tachycardia, Cardiac Troponin, ST Segment Depression, Coronary Artery Disease
To cite this article
Pan Yun, Chen Dongdong, Advances in the Value of Cardiac Troponin and ST Segment Depression in Predicting Coronary Artery Disease in Patients with Paroxysmal Supraventricular Tachycardia, Cardiology and Cardiovascular Research. Vol. 4, No. 3, 2020, pp. 127-130. doi: 10.11648/j.ccr.20200403.18
Copyright
Copyright © 2020 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association [J]. European heart journal 2012, 33 (21): 2719-2747.
[2]
Orejarena LA, Vidaillet H, Jr., DeStefano F, et al. Paroxysmal supraventricular tachycardia in the general population [J]. Journal of the American College of Cardiology 1998, 31 (1): 150-157.
[3]
Mahtani AU, Nair DG. Supraventricular Tachycardia [J]. The Medical clinics of North America 2019, 103 (5): 863-879.
[4]
Dorenkamp M, Zabel M, Sticherling C. Role of coronary angiography before radiofrequency ablation in patients presenting with paroxysmal supraventricular tachycardia [J]. Journal of cardiovascular pharmacology and therapeutics 2007, 12 (2): 137-144.
[5]
Steg PG, James SK, Atar D, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation [J]. European heart journal 2012, 33 (20): 2569-2619.
[6]
Murer M, Cuculi F, Toggweiler S, et al. Elevated high-sensitivity troponin does not indicate the presence of coronary artery disease in patients presenting with supraventricular tachycardia [J]. Cardiology journal 2017, 24 (6): 642-648.
[7]
Noorvash D, Ramos R, Hatch L, et al. Assessment of the Utility of Ordering a Troponin in Low- and Intermediate-Risk Patients Presenting to the Emergency Department with Supraventricular Tachycardia: A Retrospective Chart Review [J]. The Journal of emergency medicine 2018, 55 (1): 1-6.
[8]
Bukkapatnam RN, Robinson M, Turnipseed S, et al. Relationship of myocardial ischemia and injury to coronary artery disease in patients with supraventricular tachycardia [J]. The American journal of cardiology 2010, 106 (3): 374-377.
[9]
Sayadnik M, Shafiee A, Jenab Y, et al. Predictors of High-Sensitivity Cardiac Troponin T Elevation in Patients with Acute Paroxysmal Supraventricular Tachycardia and Ischemic Heart Disease [J]. Texas Heart Institute journal 2017, 44 (5): 306-311.
[10]
Miranda RC, Machado MN, Takakura IT, et al. Elevated troponin levels after prolonged supraventricular tachycardia in patient with normal coronary angiography [J]. Cardiology 2006, 106 (1): 10-13.
[11]
Redfearn DP, Ratib K, Marshall HJ, et al. Supraventricular tachycardia promotes release of troponin I in patients with normal coronary arteries [J]. International journal of cardiology 2005, 102 (3): 521-522.
[12]
Yeo KK, Cruz L, Hong R. Tachycardia-induced elevations in cardiac troponin in the absence of coronary artery disease [J]. Hawaii medical journal 2006, 65 (3): 86-87.
[13]
Chow GV, Hirsch GA, Spragg DD, et al. Prognostic significance of cardiac troponin I levels in hospitalized patients presenting with supraventricular tachycardia [J]. Medicine 2010, 89 (3): 141-148.
[14]
Tanindi A, Cemri M. Troponin elevation in conditions other than acute coronary syndromes [J]. Vascular health and risk management 2011, 7: 597-603.
[15]
Korff S, Katus HA, Giannitsis E. Differential diagnosis of elevated troponins [J]. Heart (British Cardiac Society) 2006, 92 (7): 987-993.
[16]
Antman EM. Decision making with cardiac troponin tests [J]. The New England journal of medicine 2002, 346 (26): 2079-2082.
[17]
Moore JP, Arcilla L, Wang S, et al. Characterization of Cardiac Troponin Elevation in the Setting of Pediatric Supraventricular Tachycardia [J]. Pediatric cardiology 2016, 37 (2): 392-398.
[18]
Jeremias A, Gibson CM. Narrative review: alternative causes for elevated cardiac troponin levels when acute coronary syndromes are excluded [J]. Annals of internal medicine 2005, 142 (9): 786-791.
[19]
Musuraca G, Imperadore F, Terraneo C, et al. Pheochromocytoma mimicking a non-ST elevation acute myocardial infarction [J]. Cardiology journal 2009, 16 (4): 355-357.
[20]
Habash F, Albashaireh A, Madmani ME, et al. ST Segment Elevation and Depressions in Supraventricular Tachycardia without Coronary Artery Disease [J]. Case reports in cardiology 2018, 2018: 2716312.
[21]
Cannon RO, 3rd, Schenke WH, Quyyumi A, et al. Comparison of exercise testing with studies of coronary flow reserve in patients with microvascular angina [J]. Circulation 1991, 83 (5 Suppl): Iii77-81.
[22]
Takayanagi K, Hoshi H, Shimizu M, et al. Pronounced ST-segment depression during paroxysmal supraventricular tachycardia [J]. Japanese heart journal 1993, 34 (3): 269-278.
[23]
Lin YJ, Tai CT, Chiang CE, et al. Mechanism of repolarization change during initiation of supraventricular tachycardia [J]. Journal of cardiovascular electrophysiology 2004, 15 (11): 1233-1237.
[24]
Riva SI, Della Bella P, Fassini G, et al. Value of analysis of ST segment changes during tachycardia in determining type of narrow QRS complex tachycardia [J]. Journal of the American College of Cardiology 1996, 27 (6): 1480-1485.
[25]
Güleç S, Ertaş F, Karaoŏuz R, et al. Value of ST-segment depression during paroxysmal supraventricular tachycardia in the diagnosis of coronary artery disease [J]. The American journal of cardiology 1999, 83 (3): 458-460, a410.
[26]
Ong P, Camici PG, Beltrame JF, et al. International standardization of diagnostic criteria for microvascular angina [J]. International journal of cardiology 2018, 250: 16-20.
[27]
Taqueti VR, Di Carli MF. Coronary Microvascular Disease Pathogenic Mechanisms and Therapeutic Options: JACC State-of-the-Art Review [J]. Journal of the American College of Cardiology 2018, 72 (21): 2625-2641.
Browse journals by subject